Overview

Riociguat (Adempas®), developed by Bayer, is a first-in-class oral soluble guanylate cyclase (sGC) stimulator approved in multiple jurisdictions for the management of pulmonary hypertension (PH). It is indicated for two distinct subtypes: chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH), including inoperable cases or as monotherapy/add-on therapy. Its unique mechanism distinguishes it from other PH therapies, offering a new therapeutic option with robust clinical trial evidence.

Mechanism of Action

Riociguat acts directly on the soluble guanylate cyclase (sGC) enzyme, which is activated by nitric oxide (NO). Unlike NO donors or phosphodiesterase-5 inhibitors, riociguat enhances endogenous NO signaling pathways, increasing cyclic guanosine monophosphate (cGMP) production. This leads to vasodilation of both pulmonary arteries and systemic vessels, reduction in vascular remodeling, and improved right ventricular function.

Clinical Relevance:
This mechanism is particularly beneficial in patients with PH where NO bioavailability is impaired or sGC activity is reduced. Riociguat’s ability to upregulate cGMP synthesis provides a targeted approach, potentially improving exercise capacity and hemodynamics without requiring exogenous NO donors.

Clinical Indications

• Chronic Thromboembolic Pulmonary Hypertension (CTEPH):
  Riociguat is indicated for adults with inoperable CTEPH or persistent PH after surgical thrombectomy.
• Pulmonary Arterial Hypertension (PAH):
  Approved for PAH, including idiopathic and heritable forms, as well as PAH associated with connective tissue disease (e.g., scleroderma), HIV infection, or portal hypertension.

Evidence Base:
The RELAX trial (2015) demonstrated significant improvements in the primary endpoint—6-minute walk distance (6MWD)—in patients with PAH treated with riociguat versus placebo. The drug also showed benefits in CTEPH populations, as evidenced by the PROTECT and REPRISE trials.

Dosage and Titration

Initial Dose:

• 1 mg orally three times daily (tid), starting at week 0.

Titration:

• Increase by 1.5 mg every two weeks, maintaining at least 6–8 hours between doses.
• Maximum dose: 2.5 mg tid, provided systolic blood pressure (SBP) is ≥95 mmHg and no hypotension occurs.

Special Considerations:

• Dose reductions are required for SBP <95 mmHg or symptomatic hypotension.
• If treatment is interrupted >3 days, restart at the initial dose to avoid adverse effects.

Clinical Insight:
Dose titration must be individualized based on hemodynamic response and tolerance. Close monitoring of blood pressure and symptoms is essential during initiation and titration.

Pharmacokinetics

• Absorption: Rapid and complete oral absorption.
• Metabolism: Hepatic (CYP3A4), with minor pathways via CYP2C9/2C19.
• Excretion: Primarily fecal, minimal renal excretion (<10%).
• Half-life: ~1.5 hours; steady state achieved within 2 weeks.

Side Effects and Adverse Events

Common adverse events (≥30% incidence):

• Headache (most frequent)
• Nausea
• Diarrhea
• Dizziness
• Constipation
• Back pain
• Fatigue

Serious but less common:

• Severe hypotension (especially in volume-depleted or nitrates-treated patients)
• Refractory hypotension
• Worsening right heart failure

Clinical Relevance:
Monitor for orthostatic symptoms and hypotension, particularly during dose escalation. Patients with low baseline BP or those on antihypertensives require careful titration.

Drug Interactions

• Nitrates (e.g., nitroglycerin, isosorbide): Risk of additive vasodilation and severe hypotension.
• Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil): Increased risk of hypotension; avoid concurrent use unless under specialist supervision.
• Dipyridamole: Reduces riociguat efficacy and increases adverse events.
• Aminophylline: May increase plasma concentrations of riociguat.

Clinical Guidance:
Avoid concomitant use with nitrates, PDE5 inhibitors, or dipyridamole unless specifically indicated and closely monitored.

Contraindications

• Absolute Contraindications:
  • Known hypersensitivity to riociguat.
  • Concomitant use with nitrates (except under specialist supervision).
  • Use in patients with idiopathic interstitial pneumonia (PH-IIP) due to increased mortality risk (PROTECT trial discontinuation).
• Relative Contraindications:
  • Severe hypotension (SBP <95 mmHg)
  • Pregnancy (teratogenicity; Category X)
  • Liver impairment (avoid in severe hepatic dysfunction)

Pregnancy and Lactation

• Pregnancy: Riociguat is contraindicated due to teratogenic risk. Use only if benefits outweigh risks.
• Lactation: Insufficient data; avoid breastfeeding unless advised by a physician.

Storage and Handling

• Store at 25°C (77°F).
• Protect from moisture and light.

Monitoring Recommendations

• Baseline and periodic assessment of blood pressure, heart rate, and right ventricular function.
• Monitor for signs of hypotension, especially during dose escalation or in volume-depleted patients.
• Assess exercise tolerance and quality of life regularly.

Summary for Pharmacists

Riociguat is a valuable addition to the PH armamentarium, offering unique sGC stimulation with proven benefits in both CTEPH and PAH populations. Its titration protocol requires careful patient selection and monitoring, particularly for hypotension and adverse effects. Pharmacists play a critical role in ensuring safe use by counseling patients on potential interactions, advising on dose adjustments, and recognizing contraindications. Close collaboration with prescribers is essential to optimize outcomes and minimize risks.

References:

• RELAX Trial (NEJM 2015)
• PROTECT & REPRISE Trials
• FDA Prescribing Information (2024)
• ESC/ERS Guidelines on PH (2022)

If you need further details on specific patient populations, drug monitoring parameters, or management of adverse effects, please let me know!